D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients

Journal of the American Society of Nephrology

Volumn 9, Issue 1, 1998, Pages 90-96

  Bommer, Christiane ^a   Werle, Egon ^a   Walter Sack, Ingeborg ^a   Keller, Christine ^a   Gehlen, Frank ^a   Wanner, Christoph ^b   Nauck, Matthias ^c   März, Winfried ^c   Wieland, Heinrich ^c   Bommer, Jürgen ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DEXTROTHYROXINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIOTHYRONINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROXINE;

ADULT; AGED; ARTERIOSCLEROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOELECTROPHORESIS; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; MALE; NEPHELOMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

EID: 0031975980     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Kronenberg F: Lipoprotein(a) in renal disease: What we have, what we need, what we can forget. Nephrol Dial Transplant 10: 766-769, 1995
2. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86: 475-482, 1992
3. Masarei JRL, Rouse IL, Lynch WJ, Robertson K, Vandongen R, Beilin LJ: Effect of lacto-ovo-vegetarian diet on serum concentrations of cholesterol, triglyceride, HDL-C, HDL-2-C, HDL-3-C, and Lp(a). Am J Clin Nutr 40: 468-479, 1984
4. Vessby B, Kostner G, Lithell H, Thomis J: Diverging effects of cholestiramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis 44: 61-71, 1982
5. Thiery J, Armstrong VW, Schleef J, Creutzfeld C, Creutzfeld W, Seidel D: Serum lipoprotein Lp(A) concentrations are not influenced by an HMG-CoA reductase inhibitor. Klin Wochenschr 66: 462-463, 1988
6. Ramires JAF, Mansur AP, Solimene MC, Maranhao R, Chamone D, da Luz P, Pileggi F: Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia. Int J Cardiol 48: 115-120, 1995
7. Dallongeville J, Fruchart JC, Pfister P, Bard JM: Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). J Intern Med 236: 95-101, 1994
8. Gurakar A, Hoeg JM, Kostner GM, Papadopoulos NM, Brewer HB: Levels of lipoprotein (a) decline with neomycin niacin treatment. Atherosclerosis 57: 293-301, 1985
9. Jones PH, Pownall HJ, Patsch W, Herd JA, Farmer JA, Payton-Ross C, Kimball KT, Gotto AM, Morrisett JD: Effect of gemfibrozil on levels of lipoprotein(a) in Type II hyperlipoproteinemic subjects. J Lipid Res 37: 1298-1308, 1996
10. Gavish D, Breslow JL: Lipoprotein(a) reduction by N-acetylcysteine. Lancet 337: 203-204, 1991
11. Kuhl H, März W, Jung-Hoffmann C, Weber J, Siekmeier R, Groß W: Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive: Divergent changes in apolipoprotein B and E and transient decrease in Lp(a). Contraception 47: 69-83, 1993
12. Hanggi W, Riesen W, Birkhaeuser MH: Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein(a). Eur J Clin Chem Clin Biochem 31: 645-650, 1993
13. Henriksson P, Angelin B, Berglund L: Hormonal regulation of serum Lp(a) levels: Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 89: 1166-1171, 1992
14. Locker P, Jungbluth GL, Francom SF, Hughes GS Jr, for the Lifibrol Study Group: Lifibrol: A novel lipid-lowering drug for the therapy of hypercholesterolemia. Clin Pharmacol Ther 57: 73-88, 1995
15. Dullaart RPF, van Doormaal JJ, Hoogenberg K, Sluiter WJ: Triiodothyronine rapidly lowers plasma lipoprotein(a) in hypothyroid subjects. Neth J Med 46: 179-184, 1995
16. Pazos F, Alvarez J, Rubies-Prat J, Varela C, Lasuncion MA: Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab 80: 562-566, 1995
17. Engler H, Riesen WF: Effect of thyroid function on concentrations of lipoprotein(a). Clin Chem 39: 2466-2469, 1993
18. De Bruin TW, Van Barlingen H, Van Linde-Sibenius Trip M, Van Vuurst De Vries AR, Akveld MJ, Erkelens DW: Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid and hyperthyroid subjects. J Clin Endocrinol Metab 76: 121-126, 1993
19. Nauck M, Winkler K, Wittmann C, Mayer H, Luley C, März W, Wieland H: Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol. Clin Chem 41: 731-738, 1995
20. Wanner C, Rader D, Battens W, Krämer J, Brewer HB, Schollmeyer P, Wieland H: Elevated plasma lipoprotein(a) in patients with nephrotic syndrome. Ann Intern Med 119: 263-269, 1993
21. Kohlmeier M: Lipoproteinanalyse mit Ultrazentrifuge. Ärztl Lab 32: 46-52, 1990
22. Li KM, Wilcken DE, Dudman NPB: Effect of serum lipoprotein(a) on estimation of low-density lipoprotein cholesterol by the Friedewald formula. Clin Chem 40: 571-573, 1994
23. Rakow AD, Klör HU, Küter E, Ditschuneit HH, Ditschuneit H: Treatment of type II hyperlipoproteinemia with D-thyroxine. Atherosclerosis 24: 369-380, 1976
24. Schwandt P, Weisweiler P: The effects of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia. Atherosclerosis 35: 301-306, 1980
25. Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson BA: Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. Arterioscler Thromb 13: 296-301, 1993
26. Soma M, Fumagalli R, Paoletti R, Meschia M, Carena Maini M, Crosignani P: Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women [Letter]. Lancet 37: 612, 1991
27. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, König P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91: 397-401, 1993
28. Kronenberg F, König P, Lhotta K, Öfner D, Sandholzer C, Margreiter R, Dosch E, Utermann G, Dieplinger H: Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 14: 1399-1404, 1994
29. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ: Identification of 34 apolipoprotein(a) isoforms: Differential expression of apolipoprotein(a) alleles between American blacks and whites. Biochem Biophys Res Commun 191: 1192-1196, 1993
30. Utermann G, Duba C, Menzel HJ: Genetics of the quantitative Lp(a) lipoprotein trait. II. Inheritance of Lp(a) glycoprotein phenotypes. Hum Genet 78: 47-50, 1988
31. Utermann G, Kraft HG, Menzel HJ, Hopferwieser T, Seitz C: Genetics of the quantitative Lp(a) lipoprotein trait. I. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentrations in plasma. Hum Genet 78: 41-46, 1988
32. Klausen IC, Hegedüs L, Hansen PS, Nielsen FE, Gerdes LU, Faergeman O: Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism. J Mol Med 73: 41-46, 1995
33. Staels B, Van Tol A, Chan L, Will H, Verhoeven G, Auwerx J: Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase and low density lipoprotein receptor in rats. Endocrinology 127: 1144-1152, 1990
34. Chait A, Bierman EL, Albers JJ: Regulatory role of triiodothyronine in the degradation of low density lipoprotein by cultured human skin fibroblasts. J Clin Endocrinol Metab 48: 887-889, 1979
35. Armstrong VW, Schleff J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D: Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): Kinetic analysis of posttreatment return to baseline levels. Eur J Clin Invest 19: 235-240, 1989
36. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr: Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest 91: 443-447, 1993
37. Gansevoort KF, Heeg JE, Dikkeschei FD, de Zeeuw D, de Jong PE, Dullart RP: Symptomatic antiproteinuric treatment decreases serum lipoprotein(a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 9: 244-250, 1994
38. Davidson NO, Powell LM, Wallis SC, Scott J: Thyroid hormone modulates the introduction of a stop codon in rat liver apolipoprotein B messenger RNA. J Biol Chem 263: 13482-13485, 1988
39. Lim VS, Zavala DC, Flanigan MJ, Freeman RM: Blunted peripheral tissue responsiveness to thyroid hormone in uremic patients. Kidney Int 31: 808-814, 1987
40. Gardner DF, Mars DR, Thomas RG, Bumrungsup C, Misbin RI: Iodine retention and thyroid dysfunction in patients on hemodialysis and continuous ambulatory peritoneal dialysis. Am J Kidney Dis 6: 471-476, 1986
41. 4 Syndrome" in subjects on regular hemodialysis and continuous ambulatory peritoneal dialysis. Nephron 46: 225-230, 1987
42. Dorey F, Strauch G, Gayno JP: Thyreotoxicosis due to pituitary resistance to thyroid hormones. Successful control with D-Thyroxine: A study in three patients. Clin Endocrinol Oxf 32: 221-228, 1990
43. Hamon P, Dingeon B, Jiang N-S, Orgiazzi J: Purified D-thyroxine in athyreotic patients. Lancet 341: 1477, 1993